Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN Smallpox Vaccine in Healthy, Vaccinia-naive Subjects

Trial Profile

A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN Smallpox Vaccine in Healthy, Vaccinia-naive Subjects

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Pharmacodynamics
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 18 Jan 2019 According to a Bavarian Nordic media release, in 2017, the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised an option of USD 37 million to cover development costs associated with this phase III trial required for the eventual approval of the freeze-dried MVA-BN smallpox vaccine.This trial will be initiated in the first half of 2019.
    • 05 Oct 2018 Status changed from planning to not yet recruiting.
    • 24 May 2018 According to a Bavarian Nordic media release, this study is planned to start in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top